Please login to the form below

35

Revenue 2017

Symbicort

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Symbicort was produced by AstraZeneca and Astellas.

GSK closes in on EU approval for triple COPD therapy

The benefits of Trelegy/Elebrato - delivered using the company's Ellipta dry powder inhaler - are its ability to improve lung function compared to AstraZeneca's ICS/LABA combination Symbicort (budesonide/formoterol)

Smart solutions

It is not just GSK that is under pressure. The likes of AstraZeneca’s Symbicort (budesonide and formoterol), Merck &Co’s Dulera (formoterol and mometasone) and Teva’s Qvar (beclometasone) are

Deal Watch March 2017

In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD)

GSK files first application for triple COPD therapy

marketplace. It already has data in hand from the FULFIL trial showing it is more effective than AstraZeneca's Symbicort (formoterol and budesonide).

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 4)

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

Featured jobs

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Medical Writer: Great salary and benefits

Project Manager, Medical Communications, London: Excellent Salary

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editorial Director – Medical Education – Oxford: Negotiable

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Account Manager / Account Director: Great salary and bebefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Medical Writer, e-learning/ training, London: Excellent Salary

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Programme Executive: Salary TBC

Account Manager – Med Comms – London: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Scientific Director: Great salary and bebefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Project Manager, Medical Communications, Oxford: Excellent Salary

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...